Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 03, 2023

Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas in Reducing the Risk of Major Adverse Cardiovascular Events

The Lancet Diabetes & Endocrinology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Lancet Diabetes Endocrinol 2023 Jul 24;[EPub Ahead of Print], Y Xie, B Bowe, H Xian, T Loux, JB McGill, Z Al-Aly

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading